PSA Screening May Be Harmful for Patients With ESRD

This article originally appeared here.
PSA Screening May Be Harmful for Patients With ESRD
PSA Screening May Be Harmful for Patients With ESRD

HealthDay News — For patients with end-stage renal disease (ESRD), prostate-specific antigen (PSA) screening may be harmful, according to a study published online Dec. 23 in the Journal of the American Society of Nephrology.

Gerardo A. Vitiello, MD, from Emory University in Atlanta, and colleagues examined whether use of PSA-based screening affects time to transplantation and transplant outcomes in patients with ESRD. A total of 3,782 male patients undergoing primary renal transplant evaluation during a 10-year period were retrospectively analyzed. Patients were grouped by age according to the American Urological Association screening guidelines: <55 years, 55–69 years, and >69 years.

Overall, 63.6% of candidates underwent screening and 31.7% of candidates received kidney transplants. The researchers found that there was no correlation between PSA screening and improved post-transplant patient survival (P=0.24). In patients aged <55 and 55–69 years who had a positive screening result, PSA screening increased the time to listing and transplantation (P<0.05). The likelihood of receiving a transplant regardless of the screening outcome was reduced for PSA-screened candidates vs. those who were not screened (P<0.001).

"These data strongly suggest that PSA screening for prostate cancer may be more harmful than protective in renal transplant candidates because it does not appear to confer a survival benefit to these candidates and may delay listing and decrease transplantation rates," the authors write.

Full Text (subscription or payment may be required)